Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Up 5.36%
As of Monday, September 14, Aclaris Therapeutics, Inc.’s ACRS share price has surged by 5.36%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Commentary & Analysis
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 5.18%
As of Friday, September 11, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 6.11%
As of Wednesday, September 09, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 6.11%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Aclaris Therapeutics, Inc.’s (ACRS) Stock Is Down 5.66%
As of Wednesday, August 26, Aclaris Therapeutics, Inc.’s ACRS share price has dipped by 5.66%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Is Aclaris Therapeutics, Inc. (ACRS) Overvalued?
We dive into why Aclaris Therapeutics, Inc. (ACRS) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Financial Summary
| Share Statistics | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $830.2 | $608.6 | 43% |
|
| Shares Out (Mil) | 142.7 | 43.1 | 70% |
|
| Institutional Ownership | 96.4% | 83.7% | 70% |
|
| Float (Mil) | 109.9 | 45.1 | 63% |
|
| Beta | 0.78 | 0.73 | 46% |
|
| Avg Daily Volume (000s) | 2,588 | 309 | 86% |
|
| Price Change (52-week) |
186.3% | 65.2% | 98% |
|
| Growth | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.7% | 6.7% | 30% |
|
| Net Income (5yr) | (4.9%) | (1.5%) | 34% |
|
| EPS (5yr) | 15.1% | 15.1% | 57 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 34.4% | (15.0%) | 88% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 10 | 10 | 11 | |
| Current EPS | ($0.165) | ($0.644) | ($0.787) | |
| Month Ago EPS | ($0.167) | ($0.651) | ($0.812) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.173) | ($0.655) | ($0.829) | |
| Year/Year Chg | 9.3% | 21.5% | 48.3% | |
| Financials | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8 | $317 | 8% |
|
| Net Income (TTM) (Mil) | ($76) | ($11) | 13% |
|
| EPS (TTM) | ($0.586) | ($0.700) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($62) | ($6) | 8% |
|
| Net Cash Flow (TTM) (Mil) | ($6) | $5 | 33% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 18% |
|
| Enterprise Value (Q1) (Mil) | $775 | $524 | 38% |
|
| Valuation | ACRS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.34 | 2.60 | 84% |
|
| P/E | na | 17.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ACRS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (757.7%) | 68.8% | 0% |
|
| Net Margin | (921.5%) | 0.8% | 0% |
|
| ROA | (41.1%) | (22.5%) | 13% |
|
| ROE | (59.1%) | (21.8%) | 14% |
|
| Liabilities to Assets | 30.7% | 32.8% | 22% |
|
| F-Score | 3 | 3 | 18% |
|
Aclaris Therapeutics, Inc. did not pass any screens on 9/14/2026.
